2022
DOI: 10.3390/biology11010147
|View full text |Cite
|
Sign up to set email alerts
|

Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives

Abstract: Neurodegenerative diseases are a global health issue with inadequate therapeutic options and an inability to restore the damaged nervous system. With advances in technology, health scientists continue to identify new approaches to the treatment of neurodegenerative diseases. Lost or injured neurons and glial cells can lead to the development of several neurological diseases, including Parkinson’s disease, stroke, and multiple sclerosis. In recent years, neurons and glial cells have successfully been generated … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 41 publications
(21 citation statements)
references
References 340 publications
(294 reference statements)
0
21
0
Order By: Relevance
“…Pharmacological evaluation of Ganoderma sp. has demonstrated its antibacterial, anti-HIV, anti-inflammatory, anti-proliferative, anti-diabetic, anticancer, hypocholesterolemic, and hepato-protective potential ( Sudheer et al, 2019 ; Mominur Rahman et al, 2021 ; Rahman et al, 2022 ). These mushrooms have also been proven to be helpful in the synthesis of NPs, particularly AgNPs.…”
Section: Green Synthesis Of Nanoparticlesmentioning
confidence: 99%
“…Pharmacological evaluation of Ganoderma sp. has demonstrated its antibacterial, anti-HIV, anti-inflammatory, anti-proliferative, anti-diabetic, anticancer, hypocholesterolemic, and hepato-protective potential ( Sudheer et al, 2019 ; Mominur Rahman et al, 2021 ; Rahman et al, 2022 ). These mushrooms have also been proven to be helpful in the synthesis of NPs, particularly AgNPs.…”
Section: Green Synthesis Of Nanoparticlesmentioning
confidence: 99%
“…GIT issues such diarrhea and colitis have also been documented in 30-40% of those who have been given anti-CTLA-4 antibodies [73]. Some of the less prevalent adverse effects, such as endocrine, nephritis, pancreatitis, and neurological diseases, should not be overlooked [59,[87][88][89][90][91].…”
Section: Diversitymentioning
confidence: 99%
“…Dermatological side effects are most common during the first two weeks after starting an immune checkpoint inhibitor medication. Around six weeks after initiating medication, GIT side effects are common [88,89]. Hepatitis can emerge anywhere from 1-49 weeks after the beginning of treatment, with a median of five weeks [90].…”
Section: Hysteresismentioning
confidence: 99%
“…Glucose-lowering medicines incorporate insulin sensitizers (biguanides, metformin, and thiazolidinediones), insulin secretagogues (sulfonylureas, meglitinides), and glucosidase inhibitors (acarbose, miglitol) [ 18 ]. Most glucose-lowering treatments can cause genuine hypoglycemia, causing liver cell harm, lactic acidosis, irreversible neurological need, stomach-related pain, cerebral agony, and shakiness [ 19 , 20 , 21 ]. Therefore, researchers are attempting to foster more viable medications with fewer antagonistic impacts.…”
Section: Introductionmentioning
confidence: 99%